109 related articles for article (PubMed ID: 12804149)
1. Transferring the financial risks of pharmaceutical benefits from a large health care provider in Argentina to a consortium of pharmaceutical companies.
Cervellino JC; Corazza SB; Bignone IM; Fligman MD; Figueroa S; Roldán R; Morici P; Diez RA
Rev Panam Salud Publica; 2003 Apr; 13(4):203-13. PubMed ID: 12804149
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
[TBL] [Abstract][Full Text] [Related]
3. Lobbying Expenditures and Campaign Contributions by the Pharmaceutical and Health Product Industry in the United States, 1999-2018.
Wouters OJ
JAMA Intern Med; 2020 May; 180(5):688-697. PubMed ID: 32125357
[TBL] [Abstract][Full Text] [Related]
4. Statistical comparison of consumer drug expenditures and discretionary purchases to assess drug affordability.
Lee JA; McKercher PL
Clin Ther; 2002 Jun; 24(6):1003-16; discussion 1002. PubMed ID: 12117076
[TBL] [Abstract][Full Text] [Related]
5. How much 'skin in the game' do medicare beneficiaries have? The increasing financial burden of health care spending, 1997-2003.
Neuman P; Cubanski J; Desmond KA; Rice TH
Health Aff (Millwood); 2007; 26(6):1692-701. PubMed ID: 17978388
[TBL] [Abstract][Full Text] [Related]
6. Out-of-pocket health spending by poor and near-poor elderly Medicare beneficiaries.
Gross DJ; Alecxih L; Gibson MJ; Corea J; Caplan C; Brangan N
Health Serv Res; 1999 Apr; 34(1 Pt 2):241-54. PubMed ID: 10199672
[TBL] [Abstract][Full Text] [Related]
7. Direct-to-consumer promotion of prescription drugs. Economic implications for patients, payers and providers.
Findlay SD
Pharmacoeconomics; 2001; 19(2):109-19. PubMed ID: 11284378
[TBL] [Abstract][Full Text] [Related]
8. Cost-lowering strategies used by medicare beneficiaries who exceed drug benefit caps and have a gap in drug coverage.
Tseng CW; Brook RH; Keeler E; Steers WN; Mangione CM
JAMA; 2004 Aug; 292(8):952-60. PubMed ID: 15328327
[TBL] [Abstract][Full Text] [Related]
9. Effect of generic drug competition on the price of prescription drugs in Ontario.
Lexchin J
CMAJ; 1993 Jan; 148(1):35-8. PubMed ID: 8439888
[TBL] [Abstract][Full Text] [Related]
10. [Drug consumption and health equity in the Metropolitan Area of Buenos Aires, Argentina].
Alonso V
Rev Panam Salud Publica; 2003 Jun; 13(6):400-6. PubMed ID: 12880521
[TBL] [Abstract][Full Text] [Related]
11. The UK pharmaceutical market. An overview.
Towse A
Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432
[TBL] [Abstract][Full Text] [Related]
12. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
13. Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study.
Parker L; Karanges EA; Bero L
BMJ Open; 2019 Feb; 9(2):e024928. PubMed ID: 30782921
[TBL] [Abstract][Full Text] [Related]
14. Out-of-pocket spending on drugs and pharmaceutical products and cost-related prescription non-adherence among Canadians with chronic disease.
Hennessy D; Sanmartin C; Ronksley P; Weaver R; Campbell D; Manns B; Tonelli M; Hemmelgarn B
Health Rep; 2016 Jun; 27(6):3-8. PubMed ID: 27305075
[TBL] [Abstract][Full Text] [Related]
15. Social Security cost-of-living adjustments and the Consumer Price Index.
Burdick C; Fisher L
Soc Secur Bull; 2007; 67(3):73-88. PubMed ID: 18605219
[TBL] [Abstract][Full Text] [Related]
16. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
Patel UD; Davis MM
J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
[TBL] [Abstract][Full Text] [Related]
17. Corruption practices in drug prescribing in Vietnam - an analysis based on qualitative interviews.
Nguyen TA; Knight R; Mant A; Razee H; Brooks G; Dang TH; Roughead EE
BMC Health Serv Res; 2018 Jul; 18(1):587. PubMed ID: 30055601
[TBL] [Abstract][Full Text] [Related]
18. How does the pharmaceutical industry influence prescription? A qualitative study of provider payment incentives and drug remunerations in hospitals in Shanghai.
Yang W
Health Econ Policy Law; 2016 Oct; 11(4):379-95. PubMed ID: 26918751
[TBL] [Abstract][Full Text] [Related]
19. Spending on medicines in Israel in an international context.
Sax P
Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
[TBL] [Abstract][Full Text] [Related]
20. The high cost of medicines in Ireland. Is it time to change the pricing mechanism?
Tilson L; McGowan B; Bennett K; Barry M
Eur J Health Econ; 2004 Dec; 5(4):341-4. PubMed ID: 15452737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
